XLO Stock Forecast: Xilio Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.56
+0.67% on the day

The median 12-month analyst price target for Xilio Therapeutics, Inc. is $19. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$53.4M
Ticker Nerd rank
68/ 100
Median analyst target
$19
Analysts covering
2
Revenue$18.7M+131.2% y/y
Operating income−$3.5M
Net income−$6.4M
Free cash flow−$18.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.4%
1M
−11.5%
YTD
−15.6%
1Y
−28.0%
From 52W high
−28.8%
From 52W low
+5.9%
$7
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Xilio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
68/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Revisions
83
Quality
82
Growth
64
Momentum
46
Issuance
37
Value
26
Accruals
21

Volatility (98): The share price has been relatively steady.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26XLOHigh $21Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$16
Low
$19
Median
$21
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Oct 2026Raymond JamesInitiatesOutperform$16
6 Aug 2025Leerink PartnersInitiatesOutperform$2.00
8 Nov 2024Raymond JamesMaintainsOutperform—
30 May 2023Chardan CapitalReiteratesBuy—
11 May 2023Chardan CapitalReiteratesBuy—
27 Jan 2023Morgan StanleyMaintainsOverweight—
21 Dec 2022Chardan CapitalInitiatesBuy—
10 Nov 2022Raymond JamesMaintainsOutperform—
10 Aug 2022Morgan StanleyMaintainsOverweight—
10 Jan 2022HC Wainwright & Co.InitiatesBuy—
16 Nov 2021Cowen & Co.InitiatesOutperform—
16 Nov 2021Morgan StanleyInitiatesOverweight—
16 Nov 2021Raymond JamesInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XLO.

Market Radar

This page is one stock. Monday covers all of them.

XLO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XLO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Xilio Therapeutics, Inc. returned −28.0% against +6.9% for the S&P 500, dividends included.

XLO vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26XLOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.6×

Cheaper than 67% of US stocks

Price / sales
1.0×

Cheaper than 67% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−74.9%

Higher than 16% of US stocks

Net margin
—
Returns & dividend
Return on equity
−38.2%

Higher than 25% of US stocks

Return on assets
−19.2%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xilio Therapeutics, Inc. has a market value of $53.4M.

  • Revenue in the twelve months to 30 June 2026: $64.1M. The latest quarter grew 131.2% year on year.

  • Net income over the same four quarters: −$21.8M, a −34.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.64.

  • Free cash flow in the twelve months to 30 June 2026: −$61.3M.

  • Shares outstanding: 6.6M.

  • Trailing P/E: 11.6×.

  • Xilio Therapeutics, Inc. employs 76 people — $843K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

XLO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XLOXilio Therapeutics, Inc.$53.4M68
XBITXBiotech, Inc.$52.7M30
NORDNordicus Partners Corp.$54.4M25
BOLDBoundless Bio, Inc.$54.8M93
AVXLAnavex Life Sciences Corp.$54.8M20
OKYOOKYO Pharma Ltd.$55.0M26
AZRAzora Therapeutics, Inc.$55.0M16

Take a look at XLO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Xilio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XLO

What is the XLO stock price forecast for 2026-2027?

The median 12-month analyst price target for Xilio Therapeutics, Inc. is $19, with estimates ranging from $16 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XLO stock a buy right now?

Of the 2 analysts covering Xilio Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xilio Therapeutics, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XLO?

As at 21 Nov 2026, Xilio Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will XLO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $19, and Ticker Nerd's factor model ranks Xilio Therapeutics, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XLO stock forecast for 2030?

No analyst covering Xilio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $21 over the next 12 months.

How has XLO stock performed over the past year?

Xilio Therapeutics, Inc. returned -28.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xilio Therapeutics, Inc. do?

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies.

Company

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies. The company’s pipeline includes investigational checkpoint inhibitors, cytokines, and immune-cell engaging therapies, with programs spanning solid tumors and other cancer settings. Xilio Therapeutics also uses its proprietary platform to engineer tumor-selective molecules such as antibodies and cytokine-based candidates, which are intended to support more precise immune responses. Based in Waltham, Massachusetts, Xilio Therapeutics plays a role in advancing next-generation oncology treatments across the biotechnology and pharmaceutical markets.

CEO Dr. Rene Russo BCPS, Pharm.D. · 76 employees · United States · https://xiliotx.com